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Elongation factor EF-Tu from Escherichia co/i was labelled with N-[‘4C]tosyl-L-phenylalanylchloro- 
methane, digested with trypsin and the peptides obtained separated by HPLC. The only radioactive peak 
recovered corresponded to tryptic peptide containing residues 75-98. Sequencing of the peptide by 
automated Edman degradation identified cysteine 81 as the site of N-tosyl-L-phenylalanylchloromethane 
modification. These results confirm the importance of this residue for the interaction 
with aminoacyl-tRNAs. 
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1. INTRODUCTION 
N-Tosyl-L-phenylalanylchloromethane (TPCK) 
can be used as a specific irreversible inhibitor of 
elongation factor EF-Tu from Escherichia colt’ and 
Bacillus stearothermophilus [l-3]. This compound 
destroyed the ability of the factor to bind 
aminoacyl-tRNA [4,5], presumably by affecting 
the cysteine residue important for the interaction 
with aminoacyl-tRNAs [3,6,7]. 14C-Labelled 
TPCK was shown to form a covalent equimolar 
complex with EF-Tu [7], and this fact established 
the inhibitor as a specific reagent to assay its in- 
teractions with aminoacyl-tRNAs and their 
analogues [8,9]. 
Here we report that TPCK modifies specifically 
cysteine residue 8 1 [ 10,111 in EF-Tu from E. coli B. 
Abbreviations: TPCK, N-tosyl-L-phenylalanylchloro- 
methane or L-1-tosylamido-2-phenylethyl chloromethyl 
ketone; EF-Tu, elongation factor Tu; HPLC, high- 
performance liquid chromatography; PTH, phenylthio- 
hydantoine 
Labelling of EF-TueGDP with [14C]TPCK: 
238 nmol crystalline EF-Tu. GDP were washed 
with 5 ml solution containing 42% saturated am- 
monium sulphate, 20 mM Tris-HCl (pH 7.6), 
10 mM magnesium acetate, 5 mM 2-mercapto- 
ethanol and 10 ,uM GDP. The sediment of crystals 
was dissolved in 5 ml buffer containing 20 mM 
Tris-HCI (pH 8.1), 10 mM magnesium acetate, 
100 mM ammonium chloride and 60pM GDP; 
100 ~1 solution was removed as a control, and 
methanol was added to 4% final cont. To the rest 
of the solution, 2 pmol [r4C]TPCK in methanol 
were added (final cont. of methanol was 4%) and 
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Tryptic peptide 
2. MATERIALS AND METHODS 
The preparation of crystalline EF-Tu - GDP, 
14C-labelled TPCK (4.2 Ci/mol), tRNA from E. 
coli B and [14C]Phe-tRNA (270 Ci/mol) has been 
described in [3,8]. GDP was from Merck (FRG), 
polybrene was from Sigma Chemical Co. (USA), 
trifluoroacetic acid from Rathburn (Scotland). 
Nucleosil ODS 5 Frn was from Macherey-Nagel 
(FRG) and TPCK-trypsin was the product of 
Worthington (USA). 
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incubation took place for 5 h at 4°C. Both samples 
were dialysed against a series of buffers containing 
1 mM 2-mercaptoethanol and decreasing concen- 
tration of Tris-HCl and magnesium acetate 
(pH 7.9), tested for their activity in the 
phenylalanine polymerization assay and freeze- 
dried. The procedure for reduction, carboxy- 
methylation with iodoacetic acid and tryptic 
digestion (enzyme/substrate ratio 1 : 100, w/w) of 
EF-Tu will be described elsewhere. 
Amino acid analysis on Beckman 121-M Amino 
Acid Analyzer and sequencing of peptides in the 
presence of polybrene in a Beckman 890C se- 
quencer were as in [12]. Peptides from the 
lyophilized tryptic digest were separated on a col- 
umn (0.8 x 25 cm) of Nucleosil ODS 5 pm par- 
ticles using 0.1% trifluoroacetic acid and a gra- 
dient of ethanol at 50°C [13]. Identification of 
PTH derivatives of amino acids was performed by 
HPLC as in [ 141. All separations by HPLC were 
performed on a Hewlett-Packard HP 1084B 
instrument. 
EF-Tu(Fg) 
Fig. 1. Effect of TPCK on EF-TU activity. Control 
(M) or [‘4C]TPCK-treated (M) EF-TU were 
assayed for the activity to promote the poly(U)-directed 
phenylalanine polymerization as in [3] except that the 
reaction mixture (80 ~1) contained 10 pmol [‘4C]Phe- 
tRNA (5400 cpm) and incubation took place for 7 min 
at 35°C. [‘4C]TPCK-labelled EF-Tu. 
Fig. 2. HPLC of the tryptic digest of elongation factor 
EF-Tu from E. co/i B: 2 nmol tryptic digest of EF-Tu 
were dissolved in 90 ~10.1% TFA, mixed with the same 
volume of 96% ethanol, the mixture was centrifuged and 
the supernatant applied on the column. No radioactivity 
was detected in a tiny sediment. Absorbance at 220 nm 
was recorded and radioactivity in 100,~l aliquots from 
each fraction was measured: (a) control EF-Tu; (b) 
3. RESULTS AND DISCUSSION 
Treatment of EF-Tu with 14C-labelled TPCK 
resulted in the almost complete loss of its ability to 
promote poly(U)-dependent polyphenylalanine 
formation (fig. 1). In the same sample, the incor- 
poration of -0.75 TPCK molecule/factor 
molecule was detected as determined by the stan- 
dard TPCK-assay procedure [8,9]. 
To determine the amino acid residue modified 
by TPCK, the labelled protein, extensively dialyzed 
to remove unreacted TPCK was lyophilized, reduc- 
ed, carboxymethylated with iodoacetic acid, sub- 
jected to tryptic digestion and the digest separated 
by HPLC chromatography. A typical chromato- 
gram of -2 nmol digest is shown in fig. 2. The 
chromatographic profile of the digest of TPCK- 
treated EF-Tu (fig. 2b) revealed the presence of a 
new distinct peak (indicated by arrow) which could 
not be detected in the hydrolyzate of control un- 
treated protein (fig. 2a). Furthermore, measure- 
ment of the radioactivity of all the individual frac- 
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tions obtained from the chromatography showed 
that the new peak was the only one containing 
radioactivity. However, we observed a substantial 
decrease in the amount of peak no. 15 in the 
hydrolyzate of TPCK-treated EF-Tu as compared 
to the same peak in the control sample. No other 
differences between the two chromatograms were 
detected. 
The amino acid analysis of the radioactively 
labelled fraction gave the following composition 
(residues/molecule): Asx 1.9, Pro 0.95, Gly 1.2, 
Ala 2.0, Val 1.6, Tyr 1.6, Lys 1.0 and His 2.7. By 
dansylation of -1 nmol peptide, the histidine 
residue was determined as the N-terminal amino 
acid. These analyses identified tryptic peptide T13 
containing residues 75-89 (see the nomenclature in 
[ 111) as the only peptide present in the radioactive 
peak. The failure to detect the cysteine residue 
which is also present in the native peptide already 
suggested that this amino acid could be the target 
of TPCK modification. This agrees with the 
finding that there is a loss of 0.5-0.6 cysteine resi- 
due (determined as cysteic acid) in the amino acid 
composition of TPCK-treated EF-Tu (J.J., unpub- 
lished). 
The isolated radioactive peptide was further 
sequenced by automated Edman degradation. In 
each successive step, the radioactivity was meas- 
ured, and the phenylthiohydantoine derivatives of 
amino acids obtained were identified by HPLC 
[14] (fig. 3). Almost no radioactivity was detected 
in the first 6 degradation steps comprising residues 
75-80. This excludes His-75 and His-78 as the 
potential targets of TPCK reagent [ 151. The analy- 
sis of PTH-derivatives of degraded amino acids in 
individual steps also confirmed the established se- 
quence of this part of T13 peptide [lo, 111. In step 
7, the peak of radioactivity was recovered, clearly 
indicating that [r4C]TPCK modifies residue 7 of 
the tryptic peptide T13, which corresponds to 
cysteine-81. TPCK has also been reported to 
modify the cysteine residue in the active site of 
papain [16]. 
However, the degradation of TPCK-modified 
cysteine-81 by automated Edman procedure 
presented technical problems. This is indicated by 
the presence of a continuous tail of radioactivity 
in all the steps following step 7 as well as by the 
lower yield (-6-times) of PTH amino acids in these 
steps in comparison to steps l-6 (not shown). 
-0 
His Ala Vat Pro His Asp Val PTH-amino 
- Gly Ala Tyr Lys acid 
I 3 5 7 9 II 13 15 
Step No 
Fig. 3. Edman degradation of [ 14C]TPCK-labelled tryp- 
tic peptide T13: -50 nmol [‘4C]TPCK-labelled peptide 
T13 (180 000 cpm) were subjected to automated Edman 
degradation procedure. PTH amino acids were iden- 
tified by HPLC as in section 2. 
Nevertheless, the identity of each of them was 
established with certainty, thus confirming the 
known sequence of this part of the molecule. That 
His-84 is not modified by TPCK is suggested by the 
lack of increase of radioactivity in step 10 and by 
the recovery of PTH histidine residue in this step, 
However, in assaying step 7 by the HPLC 
chromatography system currently used for the 
identification of PTH amino acids [14] no amino 
acid residue was recovered. TPCK-modified PTH- 
cysteine represents thus an intractable compound 
which disturbs the usual Edman degradation pro- 
cedure and binds strongly to the HPLC column. A 
thiazine derivative of the cysteine, similar to that 
identified in the study on N-tosylglycylchloro- 
methane-modified cysteine [17], may be formed, 
but ours is certainly more hydrophobic. This may 
also explain the distinct shift in the elution time of 
tryptic peptide T13 following TPCK-modification 
from its standard position in peak 15 on the 
chromatogram to a completely new location 
(fig. 2). The lack of complete disappearance of 
peak 15 after TPCK-treatment is due to the 
presence of another tryptic peptide eluting at this 
position, namely T39 and of a small fraction of un- 
modified peptide T13 (J.J., T.E.P., unpublished). 
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These results show that TPCK reacts specifically 
with cysteine 81 in EF-Tu from E. cofi B. This fin- 
ding confirms the assumptions [3,6-9,181 concern- 
ing the importance of this residue of the factor for 
its interaction with aminoacyl-tRNAs. This view is 
further supported by indications that TPCK 
modification of cysteine-81 is blocked by 
3’-terminal analogues of tRNAs [8,9]. 
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